NEW YORK - Becton Dickinson (NYSE:BDX) reported fourth quarter earnings that beat analyst expectations, but its stock dipped slightly Thursday, down 0.82%.
The Franklin Lakes, New Jersey-based company posted adjusted earnings per share of $3.81 for the quarter ended September 30, surpassing the analyst consensus of $3.77. Revenue rose 6.9% year-over-year to $5.44 billion, also topping expectations of $5.37 billion.
For fiscal year 2025, Becton Dickinson forecasts adjusted EPS of $14.25 to $14.60, straddling the $14.34 analyst estimate. The company projects revenue of $21.9 billion to $22.1 billion, above the $21.75 billion consensus.
"In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences (NYSE:EW)' Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals," said Tom Polen, chairman, CEO and president of BD.
The company's Q4 revenue growth was driven by an 11.1% increase in its Medical (TASE:PMCN) segment and a 4.7% rise in its Interventional segment. The Life Sciences segment saw more modest growth of 0.7%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.